RSS-Feed abonnieren
DOI: 10.1055/s-0032-1301901
Effects of Erythropoietin on Glucose Metabolism
Publikationsverlauf
received 10. Juni 2011
accepted after second revision 12. Januar 2012
Publikationsdatum:
20. Februar 2012 (online)
![](https://www.thieme-connect.de/media/hmr/201204/lookinside/thumbnails/10.1055-s-0032-1301901-1.jpg)
Abstract
We purposed to determine the impact of erythropoietin on altering glucose metabolism in the settings of in vitro and in vivo experiments. The acute effect of erythropoietin on lowering blood glucose levels was studied in animal experiments. In [3H]-deoxy-d-glucose isotope studies we measured glucose uptake with insulin and erythropoietin using 3T3-L1 cells cultured under normal or high glucose conditions. Altered activation of Akt and ERK pathways was evaluated in immunoblot analyses. Immunocytochemistry was conducted to determine the glucose transporter 4 translocation to the plasma membrane. Addition of erythropoietin significantly lowered blood glucose levels in vivo in rats. The glucose uptake was markedly increased by erythropoietin treatment (at concentrations 0.15, 0.3, and 0.625 ng/ml) in adipocytes grown in high glucose medium (p<0.05), but it remained unaltered in cells under normal glucose conditions. Significant increase of phosphorylation of ERK and Akt was detected due to erythropoietin (p<0.05). Co-administration of erythropoietin and insulin resulted in higher phosphorylation of Akt and [3H]-deoxy-d-glucose uptake in adipocytes than insulin treatment alone. We found that erythropoietin induced the trafficking of glucose transporter 4 to the plasma membrane. Our data showed that erythropoietin significantly decreased blood glucose levels both in vivo and in vitro, in part, by increasing glucose uptake via the activation of Akt pathway. Preliminary data revealed that adipocytes most likely exhibit a specific receptor for erythropoietin.
-
References
- 1 Morse BS, Stohlman Jr F. Regulation of erythropoiesis. 18. The effect of incristine and erythropoietin on bone marrow. J Clin Invest 1966; 45: 1241-1250
- 2 Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141: 14-31
- 3 Youssoufian H, Longmore G, Neumann D, Yoshimura A, Lodish HF. Structure, function, and activation of the erythropoietin receptor. Blood 1993; 81: 2223-2236
- 4 Wojchowski DM, Sathyanarayana P, Dev A. Erythropoietin receptor response circuits. Curr Opin Hematol 2010; 17: 169-176
- 5 Fu P, Jiang X, Arcasoy MO. Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway. Biochem Biophys Res Commun 2009; 13; 379: 696-701
- 6 Yamaji R, Okada T, Moriya M, Naito M, Tsuruo T, Miyatake K, Nakano Y. Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 1996; 239: 494-500
- 7 Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997; 76: 105-116
- 8 Lewczuk P, Hasselblatt M, Kamrowski-Kruck H, Heyer A, Unzicker C, Sirén AL, Ehrenreich H. Survival of hippocampal neurons in culture upon hypoxia: effect of erythropoietin. Neuroreport 2000; 11: 3485-3488
- 9 Nagai A, Nakagawa E, Choi HB. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 2001; 60: 386-392
- 10 Fenjves ES, Ochoa MS, Cabrera O, Mendez AJ, Kenyon NS, Inverardi L, Ricordi C. Human, nonhuman primate, and rat pancreatic islets express erythropoietin receptors. Transplantation 2003; 75: 1356-1360
- 11 Hardee ME, Rabbani ZN, Arcasoy MO, Kirkpatrick JP, Vujaskovic Z, Dewhirst MW, Blackwell KL. Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity. Mol Cancer Ther 2006; 5: 356-361
- 12 Tsai PT, Ohab JJ, Kertesz N, Groszer M, Matter C, Gao J, Liu X, Wu H, Carmichael ST. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci 2006; 26: 1269-1274
- 13 Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 1998; 95: 4635-4640
- 14 Lu KY, Ching LC, Su KH, Yu YB, Kou YR, Hsiao SH, Huang YC, Chen CY, Cheng LC, Pan CC, Lee TS. Erythropoietin suppresses the formation of macrophage foam cells: role of liver X receptor alpha. Circulation 2010; 121: 1828-1837
- 15 Hojman P, Brolin C, Gissel H, Brandt C, Zerahn B, Pedersen BK, Gehl J. Erythropoietin over-expression protects against diet-induced obesity in mice through increased fat oxidation in muscles. PLoS One 2009; 12; 4: e5894
- 16 Allegra V, Mengozzi G, Martimbianco L, Vasile A. Early and late effects of erythropoietin on glucose metabolism in maintenance hemodialysis patients. Am J Nephrol 1996; 16: 304-308
- 17 Bianchi R, Buyukakilli B, Brines M, Savino C, Cavaletti G, Oggioni N, Lauria G, Borgna M, Lombardi R, Cimen B, Comelekoglu U, Kanik A, Tataroglu C, Cerami A, Ghezzi P. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc Natl Acad Sci USA 1999; 101: 823-828
- 18 Nakao T, Matsumoto H, Okada T, Han M, Hidaka H, Yoshino M, Shino T, Yamada C, Nagaoka Y. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 1998; 37: 826-830
- 19 Brown JN, Kemp DW, Brice KR. Class effect of erythropoietin therapy on hemoglobin A(1c) in a patient with diabetes mellitus and chronic kidney disease not undergoing hemodialysis. Pharmacotherapy 2009; 29: 468-472
- 20 Katz O, Stuible M, Golishevski N, Lifshitz L, Tremblay ML, Gassmann M, Mittelman M, Neumann D. Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models. J Endocrinol 2010; 205: 87-95
- 21 Czech MP, Buxton JM. Insulin action on the internalisation of the GLUT4 glucose transporter in isolated rat adipocytes. J Biol Chem 1993; 268: 9187-9190
- 22 Fisher MD, Frost SC. Translocation of GLUT1 does not account for elevated glucose transport in glucose-deprived 3T3-L1 adipocytes. J Biol Chem 1996; 271: 11806-11809
- 23 Rigalleau V, Blanchetier V, Aparicio M, Baillet L, Sneed J, Dabadie H, Gin H. Erythropoietin can deteriorate glucose control in uraemic non-insulin-dependent diabetic patients. Diabetes Metab 1998; 24: 62-65
- 24 Ng JM, Cooke M, Bhandari S, Atkin SL, Kilpatrick E. The effect of iron and erythropoietin treatment on the HbA1c of patients with diabetes mellitus and chronic kidney disease. Diabetes Care 2010; 33: 2310-2313
- 25 Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 2005; 15: 146-155
- 26 Burén J, Liu HX, Lauritz J, Eriksson JW. High glucose and insulin in combination cause insulin receptor substrate-1 and -2 depletion and protein kinase B desensitisation in primary cultured rat adipocytes: possible implications for insulin resistance in type 2 diabetes. Eur J Endocrinol 2003; 148: 157-167
- 27 Rondinone CM, Wang LM, Lonnroth P, Wesslau C, Pierce JH, Smith U. Insulin receptor substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1997; 94: 4171-4175
- 28 Toba H, Sawai N, Morishita M, Murata S, Yoshida M, Nakashima K, Morita Y, Kobara M, Nakata T. Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat. Eur J Pharmacol 2009; 612: 106-114
- 29 Rasic-Milutinovic Z, Perunicic-Pekovic G, Cavala A, Gluvic Z, Bokan L, Stankovic S. The effect of recombinant human erythropoietin treatment on insulin resistance and inflammatory markers in non-diabetic patients on maintenance hemodialysis. Hippokratia 2008; 12: 157-161
- 30 Cayla J, Lavoie C, Gareau R, Duvallet A. Effects of recombinant erythropoietin (r-HuEPO) on plasma glucose concentration in endurance-trained rats. Acta Physiol Scand 1999; 166: 247-249